Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Disease of the Month- Juvenile Arthritis
Disease of the Month- Juvenile Arthritis
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots brings this month a summary of Juvenile arthritis, an autoimmune inflammatory disease   July is observed…
July 13, 2023
Insights+ Key Biosimilars Events of June 2023
Insights+ Key Biosimilars Events of June 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of June, Samsung Bioepis presented results of SB12…
July 5, 2023
PharmaShots' Key Highlights of Second Quarter 2023
PharmaShots’ Key Highlights of Second Quarter 2023
Shots: The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9B The second quarter of the year also showcases multiple approvals of the therapies…
July 3, 2023
Top Performing Drug – Enbrel (June Edition)
Top Performing Drug – Enbrel (June Edition)
Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…
June 28, 2023
Insights+: EMA Marketing Authorization of New Drugs in May 2023
Insights+: EMA Marketing Authorization of New Drugs in May 2023
Shots: The EMA approved 3 New Chemical Entity (NCE) and 7 Biologic Drugs in May 2023, leading to treatments for patients and advances in the healthcare industry In May 2023, the major highlights drugs were Breyanzi’s Approval for relapsed or refractory large B-cell lymphoma, Ultomiris (ravulizumab) for neuromyelitis optica spectrum disorder PharmaShots has compiled a…
June 26, 2023
Insights+: The US FDA New Drug Approvals in May 2023
Insights+: The US FDA New Drug Approvals in May 2023
Shots: The US FDA approved 15 NDAs and 3 BLA in May 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 54 novel products in 2023 In May 2023, the major highlights drugs were, Ayvakit approval for Indolent Systemic Mastocytosis, Rinvoq for Active Crohn's Disease PharmaShots has…
June 21, 2023
Disease of the Month - Scleroderma
Disease of the Month – Scleroderma
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research  Continuing the series for the disease of the month, PharmaShots brings this month a summary of the disease, Scleroderma, a rare neurological disease that affects…
June 8, 2023
Insights+ Key Biosimilars Events of May 2023
Insights+ Key Biosimilars Events of May 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, Celltrion’s Yuflyma (biosimilar, adalimumab) received the…
June 7, 2023
Insights+: EMA Marketing Authorization of New Drugs in April 2023
Insights+: EMA Marketing Authorization of New Drugs in April 2023
Shots: The EMA approved 8 New Chemical Entity (NCE) and 3 Biologic Drugs in April 2023, leading to treatments for patients and advances in the healthcare industry In April 2023, the major highlights drugs were Rinvoq’s Approval for active Crohn's Disease, Opzelura for non-segmental vitiligo with facial involvement in adults and adolescents PharmaShots has compiled…
May 25, 2023
Top Performing Drug – Trikafta/Kaftrio (May Edition)
Top Performing Drug – Trikafta/Kaftrio (May Edition)
Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Trikafta/Kaftrio as the top-performing drug of the month Trikafta is a combination of ivacaftor, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis in pediatric patients who have at least one…
May 24, 2023
Load more